Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05971381 · ClinicalTrials.gov registry record · NA
Repigmentation of Stable Vitiligo Lesions Using Spray-On Skin™ Cells
A NA study of Vitiligo, sponsored by Avita Medical.
- Completed
- Registry status
- NA
- Development phase
- 109
- Enrollment target
- 17
- Study locations
NCT05971381: Completed NA study of Vitiligo, sponsored by Avita Medical.
NCT05971381 is a NA study of Vitiligo that has completed, run by Avita Medical. The registered enrollment target is 109 participants, below the 1,117-participant average among 15 other Vitiligo trials with a reported enrollment target (90% lower). The trial reports 17 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05971381, a NA study of Vitiligo, has completed, sponsored by Avita Medical.
- COMPLETED
- Registry status
- NA
- Development phase
- 109 participants
- Enrollment target
- 17
- Study locations
Study Summary
To evaluate repigmentation and quality of life after treatment of stable vitiligo lesions using the RECELL Device.
Primary Outcome
Central Review Committee categorization of index area repigmentation
Conditions Studied
Interventions
- DEVICE RECELL® Autologous Cell Harvesting Device
Study Locations (17)
California
- University of California, Irvine - Irvine
- West Dermatology Research Center - San Diego
- Sutter Health - Sunnyvale
- California Dermatology Institute - Thousand Oaks
Michigan
- Hamzavi Dermatology - Canton
- Henry Ford Health - Detroit
- Grekin Skin Institute - Warren
Florida
- Siperstein Dermatology Group - Boynton Beach
- Skin Care Research, LLC - Hollywood
Maryland
- Dermatologic Surgery Center of Washington - Chevy Chase
- Maryland Laser, Skin & Vein Institute - Hunt Valley
New York
- The Dermatology Specialist - New York
- Mount Sinai - New York
Arizona
- Affiliated Dermatology - Scottsdale
Colorado
- Clarity Dermatology - Castle Rock
Massachusetts
- University Of Massachusetts - Worcester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2023-08-14 |
| Est. Completion | 2025-01-31 |
| Phase | NA |
What the finished NCT05971381 record still lists
NCT05971381 is an interventional study that assigns participants to a tested intervention. The registered 109 participants enrollment target is mid-sized for trials with a published cap, below the 1,117-participant average among 15 other Vitiligo trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Vitiligo appearing as the primary indexed condition, and to 1 intervention - of which RECELL® Autologous Cell Harvesting Device is the first listed.
NCT05971381 lists 17 locations in 9 states (California, Michigan, Florida).
Frequently Asked Questions
What is clinical trial NCT05971381 about?
NCT05971381 is a clinical study titled "Repigmentation of Stable Vitiligo Lesions Using Spray-On Skin™ Cells". To evaluate repigmentation and quality of life after treatment of stable vitiligo lesions using the RECELL Device.
What is the current status of trial NCT05971381?
This trial is currently completed. It is a NA study. The enrollment target is 109 participants. The study started on 2023-08-14. Estimated completion is 2025-01-31.
What conditions does trial NCT05971381 study?
This clinical trial studies the following conditions: Vitiligo.
What interventions are being tested in trial NCT05971381?
The interventions under investigation include: RECELL® Autologous Cell Harvesting Device (DEVICE).
Who is sponsoring clinical trial NCT05971381?
This trial is sponsored by Avita Medical, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05971381 being conducted?
This trial has 17 study locations across Arizona, California, Colorado, Florida, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vitiligo
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05971381's enrollment target sits among peer trials
109 6th of 15 higher than 10 of 15 other Vitiligo trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Vitiligo trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Photocil (Topical) for the Treatment of Vitiligo
COMPLETED · NA
-
Early Molecular Changes in Vitiligo After Narrowband Ultraviolet Therapy
COMPLETED · NA
-
A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo
RECRUITING · Phase 1
-
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
RECRUITING · Phase 3
-
The Gut and Skin Microbiome in Vitiligo Disease Progression
RECRUITING
-
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02421380 · 109 participants · NA
Characterization of Hyperpolarized Pyruvate MRI Reproducibility
- NCT04526600 · 109 participants · NA
Fidgeting and Attentional and Emotional Regulation in ADHD
- NCT04835584 · 109 participants · Phase 1
KRT-232 and TKI Study in Chronic Myeloid Leukemia
- NCT06626516 · 109 participants · Phase 1
Tebentafusp-tebn With LDT in Metastatic UM
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI